Biotechnology company Biocytogen Pharmaceuticals (Beijing) Co Ltd (HKEX:02315) said on Wednesday that it has granted precision medicine oncology company IDEAYA Biosciences Inc (Nasdaq:IDYA) an option for an exclusive worldwide licence to develop a potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody drug conjugate (BsADC) programme.
B7H3/PTK7 is co-expressed in multiple solid tumour types, including lung, colorectal, and head and neck cancers.
Under the agreement, Biocytogen is eligible for an upfront fee, option exercise fee, development and regulatory milestones, and royalties. Total potential payments could reach USD406.5m.
The B7H3/PTK7 BsADC programme has potential as a monotherapy and in combination with IDEAYA's DNA Damage Repair (DDR) pipeline, including PARG inhibitor IDE161. A development candidate nomination is expected in the second half of 2024.
Mabwell's B7-H3-targeting ADC clinical trial application receives Chinese regulatory approval
Dupixent receives approval in Japan as first biologic for COPD treatment
Vast Therapeutics' ALX1 drug candidate granted QIDP designation by US FDA
Actinium Pharmaceuticals signs Ac-225 radioisotope agreement with Eckert & Ziegler
GSK's Nucala (Mepolizumab) COPD application accepted by EMA
Everest Medicines' EVM14 IND application receives US FDA approval
Clover Biopharmaceuticals' SCB-1019 IND application receives US FDA approval
CStone Pharmaceuticals submits Type II variation application to EMA for sugemalimab
Hikma announces Health Canada approval of KLOXXADO Nasal Spray for opioid overdose treatment
Johnson & Johnson reports breakthrough overall survival data for EGFR-mutated lung cancer treatment
Altesa BioSciences granted US regulatory approval for vapendavir clinical trials
Black Diamond Therapeutics and Servier agree global licensing deal for BDTX-4933
AstraZeneca secures EU approval for Imfinzi in limited-stage small cell lung cancer